AU2016343855B2 - Compositions and methods for treatment of peroxisomal disorders and leukodystrophies - Google Patents

Compositions and methods for treatment of peroxisomal disorders and leukodystrophies Download PDF

Info

Publication number
AU2016343855B2
AU2016343855B2 AU2016343855A AU2016343855A AU2016343855B2 AU 2016343855 B2 AU2016343855 B2 AU 2016343855B2 AU 2016343855 A AU2016343855 A AU 2016343855A AU 2016343855 A AU2016343855 A AU 2016343855A AU 2016343855 B2 AU2016343855 B2 AU 2016343855B2
Authority
AU
Australia
Prior art keywords
agent
dendrimer
dendrimers
therapeutic agent
leukodystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016343855A
Other languages
English (en)
Other versions
AU2016343855A1 (en
Inventor
Seyed Ali FATEMI
Ozgul GOK
Sujatha Kannan
Kannan Rangaramanujam
Bela TURK
Fan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Kennedy Krieger Institute Inc
Original Assignee
Johns Hopkins University
Kennedy Krieger Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Kennedy Krieger Institute Inc filed Critical Johns Hopkins University
Publication of AU2016343855A1 publication Critical patent/AU2016343855A1/en
Application granted granted Critical
Publication of AU2016343855B2 publication Critical patent/AU2016343855B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016343855A 2015-10-29 2016-10-31 Compositions and methods for treatment of peroxisomal disorders and leukodystrophies Active AU2016343855B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248163P 2015-10-29 2015-10-29
US62/248,163 2015-10-29
PCT/US2016/059697 WO2017075580A1 (en) 2015-10-29 2016-10-31 Compositions and methods for treatment of peroxisomal disorders and leukodystrophies

Publications (2)

Publication Number Publication Date
AU2016343855A1 AU2016343855A1 (en) 2018-05-10
AU2016343855B2 true AU2016343855B2 (en) 2019-10-03

Family

ID=57233968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016343855A Active AU2016343855B2 (en) 2015-10-29 2016-10-31 Compositions and methods for treatment of peroxisomal disorders and leukodystrophies

Country Status (7)

Country Link
US (2) US20170119899A1 (https=)
EP (1) EP3368088B1 (https=)
JP (2) JP7088473B2 (https=)
CN (1) CN108430514B (https=)
AU (1) AU2016343855B2 (https=)
CA (1) CA3003589C (https=)
WO (1) WO2017075580A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342575B2 (ja) * 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2019118951A2 (en) * 2017-12-15 2019-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
WO2020081923A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2020142373A1 (en) * 2019-01-02 2020-07-09 Mayo Foundation For Medical Education And Research Methods and materials for treating leukodystrophies
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
PH12022552818A1 (en) * 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
US20230364244A1 (en) * 2020-07-17 2023-11-16 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to injured kidney
WO2023081750A1 (en) * 2021-11-04 2023-05-11 The Children's Hospital Of Philadelphia Compositions and methods for treating metachromatic leukodystrophy disease and related disorders
WO2024081687A2 (en) * 2022-10-12 2024-04-18 The Johns Hopkins University Method of treating lbsl by enhancing dars2 expression
CN116082153A (zh) * 2022-12-09 2023-05-09 长沙贝塔医药科技有限公司 一种丙烯酸酯类衍生物-13c的制备方法
EP4410284A1 (en) * 2023-02-02 2024-08-07 Apteeus Compound and method for the treatment of zellweger spectrum disorder
CN117643581A (zh) * 2023-11-29 2024-03-05 徐州医科大学 白藜芦醇在制备激活sirt1基因的药物中的应用
WO2025240286A1 (en) * 2024-05-14 2025-11-20 Washington State University Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031848A1 (en) * 2006-05-22 2008-02-07 Elan Pharmaceuticals, Inc. Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
US20120003155A1 (en) * 2009-06-15 2012-01-05 National Institutes Of Health Dendrimer based nanodevices for therapeutic and imaging purposes
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015027068A1 (en) * 2013-08-21 2015-02-26 Concordia University Dendrimer-resveratrol complex

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69612755T2 (de) 1995-02-07 2001-08-23 Brusilow Enterprises, Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
AU6269799A (en) * 1998-09-28 2000-04-17 Johns Hopkins University, The Adrenoleukodystrophy treatments and drug screening
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2596112A4 (en) 2010-07-21 2015-01-21 Cumberland Pharmaceuticals Inc ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
CN106659798A (zh) * 2014-08-13 2017-05-10 约翰霍普金斯大学 树枝状聚合物组合物和在治疗神经与cns病症中的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031848A1 (en) * 2006-05-22 2008-02-07 Elan Pharmaceuticals, Inc. Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
WO2009046446A2 (en) * 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
US20120003155A1 (en) * 2009-06-15 2012-01-05 National Institutes Of Health Dendrimer based nanodevices for therapeutic and imaging purposes
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015027068A1 (en) * 2013-08-21 2015-02-26 Concordia University Dendrimer-resveratrol complex

Also Published As

Publication number Publication date
AU2016343855A1 (en) 2018-05-10
JP2018531965A (ja) 2018-11-01
US20170119899A1 (en) 2017-05-04
CA3003589A1 (en) 2017-05-04
CN108430514B (zh) 2023-11-03
JP7088473B2 (ja) 2022-06-21
JP2022105767A (ja) 2022-07-14
CA3003589C (en) 2021-12-07
EP3368088A1 (en) 2018-09-05
WO2017075580A1 (en) 2017-05-04
CN108430514A (zh) 2018-08-21
US20220071923A1 (en) 2022-03-10
EP3368088C0 (en) 2023-06-07
EP3368088B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US20220071923A1 (en) Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
He et al. Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis
JP6531164B2 (ja) 神経障害およびｃｎｓ障害の処置におけるデンドリマー組成物および使用
AU2015301575B2 (en) Selective dendrimer delivery to brain tumors
Cheong et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system
US20220080056A1 (en) Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
Uthaman et al. Inhibiting the cGAS-STING pathway in ulcerative colitis with programmable micelles
Haroon et al. Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury
Mathew et al. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain
Morace et al. Renal globotriaosylceramide facilitates tubular albumin absorption and its inhibition protects against acute kidney injury
US20230364244A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
CN119053344A (zh) 用于靶向递送治疗剂至神经元的树枝状聚合物组合物
Das et al. Advancement on nanoparticles-based approaches for the management of rheumatoid arthritis (RA): molecular mechanism, toxicity, and clinical perspectives
Li et al. GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice
Machtoub et al. Amyotrophic Lateral Sclerosis: Advances and Perspectives of Neuronanomedicine
McCue et al. Examining tissue-level changes in doxorubicin accumulation and nitric oxide formation in skeletal muscle and tumours in a mouse model of breast cancer
US20230338554A1 (en) Galactosylated dendrimers for targeted intracellular delivery to hepatocytes
US20250352653A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
He et al. ROS-responsive glucosylated nanodisc prodrug for efficient targeted epilepsy therapy
Xi et al. Callicarpa nudiflora-derived extracellular vesicle-like particles loaded with budesonide enhance the treatment of ulcerative colitis by regulating M1/M2 macrophage polarization
Popovich Development of Therapeutics, Models and Diagnostics for Multiple Sclerosis and Neurodegeneration Research
KR20260044564A (ko) 포비돈-프러시안 블루 나노자임을 유효성분으로 포함하는 골관절염의 예방, 치료 또는 개선용 조성물
HK40119489A (zh) 用於靶向递送治疗剂至神经元的树枝状聚合物组合物
HK1236118A1 (en) Dendrimer compositions and use in treatment of neurological and cns disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)